CASI Pharmaceuticals Inc. has announced that the Safety Monitoring Committee $(SMC)$ has recommended proceeding with the dose escalation to cohort 5 (900 mg target dose) in their Phase 1 study of CID-103, an anti-CD38 monoclonal antibody, in adults with chronic immune thrombocytopenia $(ITP)$. The recommendation follows a review of the safety profile observed in the first four dose cohorts, which showed no serious adverse events or dose-limiting toxicities. The study is designed to include up to 30 subjects and aims to assess the safety and tolerability of CID-103. CASI Pharmaceuticals plans to report clinical results at an upcoming medical congress.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CASI Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1069852) on September 08, 2025, and is solely responsible for the information contained therein.